Structural, biochemical and biophysical studies of eukaryotic soluble and membrane proteins require their production in milligram quantities. Although large-scale protein expression strategies based on transient or stable transfection of mammalian cells are well established, they are associated with high consumable costs, limited transfection efficiency or long and tedious selection of clonal cell lines. Lentiviral transduction is an efficient method for the delivery of transgenes to mammalian cells and unifies the ease of use and speed of transient transfection with the robust expression of stable cell lines. In this protocol, we describe the design and step-by-step application of a lentiviral plasmid suite, termed pHR-CMV-TetO 2 , for the constitutive or inducible large-scale production of soluble and membrane proteins in HEK293 cell lines. Optional features include bicistronic co-expression of fluorescent marker proteins for enrichment of co-transduced cells using cell sorting and of biotin ligase for in vivo biotinylation. We demonstrate the efficacy of the method for a set of soluble proteins and for the G-protein-coupled receptor (GPCR) Smoothened (SMO). We further compare this method with baculovirus transduction of mammalian cells (BacMam), using the type-A γ-aminobutyric acid receptor (GABA A R) β3 homopentamer as a test case. The protocols described here are optimized for simplicity, speed and affordability; lead to a stable polyclonal cell line and milligram-scale amounts of protein in 3-4 weeks; and routinely achieve an approximately three-to tenfold improvement in protein production yield per cell as compared to transient transduction or transfection.
Introduction
Technologies for mammalian transient or stable cell line expression have greatly facilitated the production of stabilized and correctly folded recombinant eukaryotic proteins 1 . These proteins are often large, have a multi-domain architecture, and contain numerous post-translational modifications (PTMs) such as O-or N-linked glycosylation 2 . Accordingly, such proteins are best expressed in native cell types that contain the necessary cellular machinery for protein synthesis, folding and quality control; PTMs; and correct subcellular targeting, as well as a near-native membrane and lipid environment.
Previously, we have reported protocols for efficient transient protein expression in mammalian cells using the pHLsec plasmid 3 . This plasmid and its derivatives have now been successfully used for >10 years within the Division of Structural Biology (STRUBI) at Oxford, and have been distributed to numerous other labs. During this period, limitations associated with large-scale transient protein expression in HEK293T cells have also become apparent: large-scale plasmid preparation became increasingly costly; the procedure is fairly laborious and generates considerable plastic and biological waste. The volumes of biomass and expression media typically required, and large number of plastic roller bottles often used for a given target, add up to substantial financial and environmental burdens. In our experience, large-scale transient transfection efficiencies using polyethylenimine (PEI) are typically limited to~60-75%, meaning that approximately one-third of the total cell mass is wasted.
The generation of stably transfected cell lines overcomes many disadvantages associated with transient transfection 4 . It has, however, one important drawback; the time frame for establishing a monoclonal cell line through rigorous selection and expansion is~8-10 weeks for each construct 4 , which substantially hampers achievement of a high sample throughput.
An ideal method would combine the ease of use and speed of transient transfection with the robust expression of stable cell lines. The use of lentiviruses, belonging to the retrovirus genus, presents such a possibility. A recombinant lentivirus, containing genetic elements from HIV, is widely used for gene delivery in medical applications 5 . Lentiviruses use the host cellular machinery to amplify and package their genetic material, and the packaged transgene is delivered to the target cell via membrane fusion. Therefore, this method circumvents the need for large-scale DNA preps and laborious transfection procedures while rapidly establishing stable genome integration of the transgene with high efficiency. Although a number of laboratories have designed customized lentiviral vectors for transgene delivery [6] [7] [8] [9] , and several companies market proprietary lentiviral expression systems, the use of lentiviral transduction for large-scale protein production is not widespread in the structural biology community, perhaps owing to a lack of proof-of-principle examples and detailed protocols.
Here, we describe step-by-step procedures for large-scale expression of soluble and membrane proteins using a lentiviral system. We have constructed a plasmid suite around the transfer plasmid pHR-CMV-TetO 2 that is specifically designed for large-scale protein expression from HEK293 cell lines and is compatible with subcloning of cDNA inserts from the pHLsec plasmid commonly used for transient transfection 3 . Use of this lentiviral method leads to the rapid (within~7 d) establishment of polyclonal cell lines that can be selected, expanded and adapted to a variety of protein expression setups (Fig. 1) . The typical lead time for protein production of~3-4 weeks compares well with transient expression 3 . We routinely observe an approximately three-to tenfold improvement in protein production yield per cell as compared with transient transfection.
Overview of the procedure
The procedure to transduce expression cells is straightforward; a lentivirus producer cell line (HEK293 Lenti-X) is transiently co-transfected with transfer (encoding the transgene of interest), envelope and packaging plasmids to generate lentiviral particles. The lentivirus-containing supernatant is then, normally without concentration, used to transduce the HEK293 target cell line (Fig. 1a) . After genomic integration of the proviral DNA and optional enrichment using cell sorting, these cells are expanded for large-scale protein expression. The procedure can be broken down into four stages (Fig. 1b) . In the first stage (Steps 1-8 and Steps [11] [12] [13] [14] , the lentivirus producer cell line is transfected, and lentiviral particles encoding the transgene(s) are collected. In the second stage (Steps 9-10 and Steps 15-21), expression cells are infected, stably transduced and expanded. In the third stage ( Step 22A(i-xiii)), adherent expression cells are expanded for large-scale soluble secreted protein expression. Alternatively, in the fourth stage ( Step 22B(i-xxii)), suspension expression cells are expanded for large-scale inducible membrane protein expression.
Features of the pHR-CMV-TetO 2 transfer plasmid
We initially developed the lentiviral transfer plasmid pHR-CMV-TetO 2 (Table 1 ) and the protocols described in this paper for high-level expression of the extracellular domain (ECD) of CD45 (protein tyrosine phosphatase receptor type C; (PTPRC)) for structural studies 10, 11 . The plasmid contains the minimally necessary cis-acting HIV components: the 5ʹ and 3ʹ long terminal repeats (LTRs), the polypurine tract (PPT), the Rev response element (RRE) and the psi (ψ) packaging signal. The genetic elements flanked by the 5ʹ and 3ʹ LTRs will be stably integrated into the host cell genome as proviral DNA ( Fig. 2 (top panel) and Supplementary Fig. 1 ).
The transfer plasmid is used in conjunction with a second-generation envelope plasmid (pMD2.G; Addgene plasmid no.12259) and a second-generation packaging plasmid (psPAX2; Addgene plasmid no. 12260). pMD2.G encodes the vesicular stomatitis virus G envelope protein (VSV-G), and its use ensures a pseudotyped lentiviral particle with high infectivity and broad host tropism 12 ; the receptor for VSV-G is the low-density lipoprotein receptor (LDLR) 13 . psPAX2 contains the minimally necessary HIV genes required for virus production: gag, pol, rev and tat.
pHR-CMV-TetO 2 was derived from the second-generation pHR-SIN-CSGW lentiviral transfer plasmid 14, 15 . To maximize restriction/ligation subcloning compatibility with our pHLsec plasmid for transient expression 3 , we first deleted all internal EcoRI, AgeI, KpnI, XhoI, SalI, XbaI, NotI and BamHI restriction sites from the pHR-SIN-CSGW backbone, using PCR. Then we placed the pHLsec Large-scale adherent cell culture and protein expression Large-scale suspension cell culture and protein expression
Step 22B(i-xxii) (Weeks 2-4)
Step 22A(i- by digesting the plasmid with EcoRI. We recommend in vivo assembly (IVA) cloning 22 , which exploits recA-independent homologous recombination between a PCR amplicon and the linearized pHR-CMV-TetO 2 vector (Supplementary Methods), as a time-and cost-efficient alternative to regular restriction/ligation subcloning.
In the empty pHR-CMV-TetO 2 plasmid, the purification tag inserted between the KpnI and XhoI restriction sites is either (i) the 3C-Avi-His6 tag (pHR-CMV-TetO 2 _3C-Avi-His6 plasmid), or (ii) the 3C-Twin-Strep tag (pHR-CMV-TetO 2 _3C-Twin-Strep plasmid) ( Table 1 and Supplementary  Fig. 2a,b) . The 3C-Avi-His6 tag consists of a sequential Avi-tag and His6-tag preceded by a human rhinovirus (HRV) 3C protease site. It allows purification of proteins using immobilized metal affinity chromatography (IMAC). Use of the Avi-tag for in vivo biotinylation of proteins is described in the 'Other applications of the method' section. The 3C-Twin-Strep tag consists of a sequential arrangement of two Strep-tag II sequences preceded by a HRV 3C protease site, and is used in conjunction with Strep-Tactin XT resin 23 (IBA) for one-step protein purification 24 . In both cases, the HRV 3C protease site allows removal of the purification tag by digestion with 3C protease, optionally combined with a reverse purification step.
Finally, the pHR-CMV-TetO 2 plasmids contain the simian vacuolating virus 40 (SV40) origin of replication (ori), as well as the SV40 large T-antigen under control of the SV40 promoter (Supplementary Fig. 1 ); these features allow autonomous episomal replication of the plasmid in mammalian cells to ensure maintenance of high plasmid copy numbers. The pHR-CMV-TetO 2 plasmids are hence also suitable for transient transfection and can be used for initial small-scale screening of expression constructs (Fig. 2c) .
Extended features of the pHR-CMV-TetO 2 transfer plasmid suite
A limitation of the lentiviral system is that the size of the transgene to be packaged is physically constrained. Viral titers decrease semi-logarithmically with increasing insert size, with an estimated drop of~1 log for every 2 kb of insert 25 . Measurable titers can, however, still be obtained with proviral 25 . We found that lentiviral titers that are obtained with (i) the HEK293 Lenti-X producer cell line, which is clonally selected to support high-level expression of viral proteins to yield higher viral titers; and (ii) proviral DNA sizes not >~8.5 kb are sufficiently high to lead to >90% transduction efficiency of HEK293 expression cells. For the pHR-CMV-TetO 2 _3C-Avi-His6 and pHR-CMV-TetO 2 _3C-Twin-Strep plasmids, this equates to an insert size of~4.3 kb between the EcoRI and XhoI sites ( Supplementary Fig. 1 ). Practically, this means that neither concentration of lentiviral titer nor selection of the polyclonal stable cell line is necessary, and that the recombinant protein-producing cell population can immediately be expanded, thereby yielding substantial time savings.
Forgoing concentration of the lentivirus-containing supernatant is time efficient, prevents any negative impact on lentiviral particle integrity and also prevents the infectious lentiviral particles from having to be taken out of the flow cabinet. Consequentially, transduction is performed at a variable multiplicity of infection (MOI; the ratio of the number of viral particles to the number of target cells) because insert size correlates strongly with viral titer and viral titer determines the MOI.
It is desirable to be able to enrich any subset of transduced cells from the total cell pool, especially when working with non-concentrated lentiviral particles encoding proviral DNA sizes >~8.5 kb, which yield lower viral titers and corresponding transduction efficiencies. Two strategies are traditionally used: antibiotic selection and enrichment by FACS. Antibiotic selection is slower, but high selection pressure allows isolation of cells with high-copy-number transgene integration 7 . We opted for FACS because it is faster and because the presence of fluorescent marker proteins can have multiple downstream applications. The use of FACS to obtain high protein-expressing clonal cell lines has long precedence [26] [27] [28] . We constructed variants of the pHR-CMV-TetO 2 plasmid that allow co-expression of fluorescent proteins (FPs) using the following two strategies.
• The 3C-mVenus-Twin-Strep variant (Table 1 ) encodes mVenus (λ EX = 515 nm; λ EM = 528 nm) as a 3C-cleavable C-terminal fusion protein, cloned in frame as a tag between the KpnI and XhoI restriction sites ( Supplementary Fig. 3 ). In this setup, there is a direct 1:1 stoichiometric correspondence between the target protein and the FP.
• The IRES-FP variants (Table 1 ; IRES-EmGFP, IRES-mRuby2 and IRES-mTurquoise2) contain an internal ribosome entry site (IRES) from the encephalomyocarditis virus (EMCV), followed by the three different FPs, to allow their expression from the same mRNA as the transgene (bicistronic expression) (Fig. 3 (top panel) and Supplementary Fig. 3 ). These FPs are the Emerald green fluorescent protein (EmGFP: λ EX = 487 nm; λ EM = 509 nm) 29 , the red fluorescent protein mRuby2 (λ EX = 559 nm; λ EM = 600 nm) 30 and the cyan fluorescent protein mTurquoise2 (λ EX = 434 nm; λ EM = 474 nm) 31 . The IRES-EmGFP, IRES-mRuby2 and IRES-mTurquoise2 sequences are cloned between the XhoI and BsiWI sites, placing them downstream of the MCS and upstream of the WPRE. A consequence of this setup is that the IRES-FP elements add~1.3 kb to the proviral DNA size and so have an impact on lentiviral titer.
To test the efficacy of the IRES-FP elements, we assembled an mRuby2-IRES-EmGFP construct ( Supplementary Fig. 4a ). Using quantitative fluorescence microscopy, we determined that expression ). Expand ('split') confluent T75 or T175 flasks containing adherent cells by removing the DMEM/F-12/10% FBS medium, washing the cells with PBS (5 or 10 mL, respectively) and incubating them with trypsin-EDTA (2 or 5 mL, respectively) for 3 min in a humidified incubator operated at 37°C with 5% CO 2 . Then gently dislodge the cells and quench the trypsin-EDTA solution using 10 or 25 mL DMEM/F-12/10% FBS medium, respectively. Pipette up and down a few times, using a sterile serological 10-mL pipette to break up any clumped cells. Finally, transfer the required number of cells (typically one-sixth of the total cell slurry) to a new T75 or T175 flask and top up the DMEM/F-12/10% FBS medium to the recommended volume (12 or 30 mL, respectively). Large-scale adherent cultures for soluble secreted protein production are performed in expanded-surface polystyrene roller bottles (2,125 cm 2 ) or in HYPERFlasks (1,720 cm 2 ). HEK293T and HEK293S GnTI − cells are maintained in DMEM/F-12/10% FBS medium during expansion and DMEM/F-12/2% FBS medium during protein expression. HEK293S GnTI − TetR cells are grown identically, except for addition of 2 μg/mL blasticidin; this maintains the selective pressure on the pcDNA6/TR genetic elements with which the HEK293S GnTI − TetR cells are stably transfected (the cell line was originally selected using 5 μg/mL blasticidin 34 , but we observe slowed cell growth at that concentration). Suspension-adapted HEK293S GnTI − and HEK293S GnTI − TetR cells are normally grown in polycarbonate Erlenmeyer baffled flasks with a filter cap, in a shaking incubator operated at 37°C with 8% CO 2 (note that this differs from the 5% CO 2 used for adherent cells). Cells are grown in FreeStyle 293/1% FBS medium. Although we add 1% (vol/vol) FBS to the FreeStyle 293 medium to facilitate the transfer from adherent to suspension culture (Step 22B(i-ix)), it does not, in principle, require supplementation. The flasks are shaken at 130 r.p.m., and the suspension does not exceed 40% of the flask volume (i.e., for a 2-L flask, a maximum suspension volume of 800 mL is used). Non-suspension-adapted HEK293 cell lines such as HEK293T will require adaptation to suspension growth over a period of several weeks 60 . Indeed, full suspension adaptation of the original HEK293 cell line to yield the HEK293S cell line took~7 months 16 . FreeStyle 293-F cells, derived from the fast-growing suspension-adapted HEK293-F cell line, are an alternative. We prefer performing lentiviral transduction in adherent culture, because suspension-adapted HEK293S GnTI − and HEK293S GnTI − TetR expression cells adapt readily from an adherent monolayer to suspension culture (Step 22B(i-ix)), and because the method relies on direct transfer of lentivirus-containing medium from the adherent HEK293T Lenti-X producer cells to the expression cells (Steps 11-17). We routinely do not use penicillin-streptomycin ('pen-strep') to prevent bacterial growth, relying instead on sterile technique and well-maintained tissue culture infrastructure. Cell lines should be regularly checked to ensure that they are authentic and not infected with mycoplasma. The American Type Culture Collection (ATCC) animal cell culture guide (https://www.atcc.org/~/media/PDFs/ Culture%20Guides/AnimCellCulture_Guide.ashx) contains a wealth of tips and techniques for culturing continuous cell lines.
PROTOCOL NATURE PROTOCOLS
2996 levels of EmGFP are~30-fold lower when placed after IRES as compared to EmGFP alone, indicating that mRNA translation initiation from an IRES element is less potent than 5ʹ cap-dependent translation ( Supplementary Fig. 4b) . Importantly, however, we found that the downstream presence of IRES-EmGFP did not adversely affect fluorescence intensity levels in the red channel and that pixel values in the red and green channels correlated with a Pearson's correlation coefficient (r) of 0.89, indicating that IRES-EmGFP fluorescence can indeed be used as a qualitative and quantitative predictor of the presence and level of the protein of interest encoded by the upstream transgene ( Supplementary Fig. 4c ). We used flow cytometry to corroborate these results; we determined a Pearson's r of 0.85 between compensated mRuby2 and EmGFP fluorescence in 35,546 single, gated HEK293 cells expressing the mRuby2-IRES-EmGFP construct ( Supplementary Fig. 4d ). To verify the inverse relation between proviral DNA size and viral titer, we performed a comparative endpoint dilution assay (Box 2) for the neuronal proteins β-NRX1 LNS6 32 and α-NRX1 ECTO-FL 33 cloned into the pHR-CMV-TetO 2 _3C-Avi-His6_IRES-EmGFP plasmid (6.1-kb and 9.6-kb proviral DNA, respectively; Fig. 3b ), and observed an~100-fold difference in viral titer (~2 logs; Fig. 3c and Supplementary Fig. 5 ). Using flow cytometry, we determined a transduction efficiency of~97% and~73%, respectively ( Fig. 3d and Supplementary Fig. 6 ). To boost transduction efficiency for α-NRX1 ECTO-FL , lentiviral particles would need to be concentrated before adding them to the expression cells. Alternatively, or additionally, cells expressing the EmGFP marker protein can be enriched using FACS, and then expanded (Box 3).
The pHR-CMV-TetO 2 plasmids are optimal for use with HEK293 cell lines
The pHR-CMV-TetO 2 plasmid and its variants are optimal for use with the HEK293 cell line and its derivatives 16 . We use the HEK293T, the N-acetylglucosaminyltransferase I-negative (GnTI − )
Box 2 | Concentration and determination of lentiviral titer • Timing~4 d
Concentration and titration of the produced lentivirus allow better control over the MOI, and detailed protocols have been described previously 61 . Approaches for titration include (i) quantitative reverse transcription polymerase chain reaction (qRT-PCR) to amplify lentiviral RNA, (ii) detection of the HIV p24 capsid protein and (iii) qPCR to amplify proviral DNA. These assays are, however, time consuming and do not reflect functional viral titers when based on quantification of viral RNA or p24. Instead, we prefer to use a rapid and simple endpoint dilution assay using fluorescence, essentially as described previously for BacMam 44, 45 . We recommend using EmGFP (pHR-CMV-TetO 2 _IRES-EmGFP plasmid variant) or mVenus (pHR-CMV-TetO 2 _3C-mVenus-Twin-Strep plasmid variant) for this purpose, as mRuby2 and mTurquoise2 are less bright, which makes it difficult to identify sparsely seeded transduced cells. However, we do not routinely concentrate lentiviruses or determine their titer, instead preferring to place the lentivirus-containing supernatant (Steps 11-14) directly on top of the expression cells (Step 15). This approach works well for proviral DNA with a size of up to~8.5 kb, saves time and prevents the virus-containing supernatant from exiting the laminar flow cabinet. IRES-FP fluorescence allows subsequent verification of transduction efficiency using fluorescence microscopy and flow cytometry, as well as FACS-based enrichment of subsets of cells from the total transduced cell pool. Procedure c CRITICAL The following titration procedure is for one 96-well black plate. It is inspired by published approaches for BacMam 44, 45 . One 96-well black plate can be used to titer four lentivirus preparations simultaneously (columns 1-3, 4-6, 7-9 and 10-12); the eight dilutions (10 0 to 10 7 ), pipetted in triplicate, fit into rows A to H. 1 Seed each well of a 96-well black plate with~4 × 10 4 HEK293T cells in DMEM/F-12/10% FBS medium, bringing them to~50% confluency. It is convenient to do this the day before collection of the lentiviral particle-containing supernatant, e.g., simultaneously with Step 9. 2 Allow the cells to attach and grow overnight at 37°C in a humidified incubator operated at 5% CO 2 . 3 Filter 1 mL of lentiviral particle-containing supernatant from Step 11 through a 0.45-μm filter unit attached to a Luer-lock syringe, and into a sterile 1.5-mL tube. 
HEK293S
34 and the HEK293S GnTI − Tet repressor protein (TetR) 34 cell lines for high-level protein production (Box 1). The latter cell line is identical to HEK293S GnTI − but in addition stably transfected with the pcDNA6/TR vector, leading to constitutive intracellular expression of TetR. TetR binds to the tetracycline response element (TRE) that is just downstream of the CMV promoter in the pHR-CMV-TetO 2 plasmids (Fig. 2a and Supplementary Figs. 1 and 3) , thereby repressing transcription of the transgene. In the pHR-CMV-TetO 2 plasmids, the TRE is composed of two repeats of the 19-bp TetO operator sequence (5ʹ-TCCCTATCAGTGATAGAGA-3ʹ). Transgene expression can then be induced ('de-repressed') by application of tetracycline or its more stable analog doxycycline (Dox); Dox binds TetR, thereby releasing it from the TRE 18, 35 . In summary, use of the pHR-CMV-TetO 2 plasmids in combination with the HEK293S GnTI − TetR cell line is particularly attractive for a number of reasons when producing mammalian proteins for structural biological purposes: (i) stable expression generally yields higher amounts of protein than transient expression; (ii) the TetO 2 -TetR system allows inducible expression, which is useful when working with toxic proteins or membrane proteins; (iii) HEK293S cells allow both suspension and adherent growth; (iv) fluorescent marker proteins allow enrichment by FACS; and (v) GnTI − ensures the presence of predominantly homogeneous high mannose-type (Man 5 GlcNAc 2 ) N-linked glycans that are sensitive to cleavage by endoglycosidase H (EndoH) or F1 (EndoF1) 2 .
Other applications of the method
Alternative promoters
The CMV-MIE promoter/enhancer is one of the strongest promoters in HEK293 cells 17 . Like other strong viral promoters, it is prone to transcriptional silencing regulated by DNA methylation after prolonged activity [36] [37] [38] . It is, however, not prominent in HEK293 cell lines within the time frame of our procedure and can be reversed by application of the DNA methyltransferase (DNMT) inhibitor 5-Aza-2ʹ-deoxycytidine (5-aza-dC). Because the CMV-MIE promoter/enhancer may not be the best choice for any given cell type 17 , we have also included pHR variants containing either the SFFV promoter (pHR-SFFV) or the CAG (CMV enhancer, chicken β-actin promoter, rabbit β-globin splice acceptor) element amplified from pHLsec 3 (pHR-CAG) ( Table 1 and Supplementary Fig. 3 ). All
Box 3 | FACS to enrich subpopulations of transduced cells FACS 62-64 is a fast and convenient method of enriching transduced cell populations. The 3C-mVenus-Twin-Strep and IRES-FP plasmid variants are specifically designed for this purpose. In this box, we provide a number of pointers for optimal experimental results.
• When performing cell sorting, we pre-fill our catch tubes with complete medium.
• We find that cell viability after sorting is greatest when using suspension cells.
• For adherent cells, we recommend using soybean trypsin inhibitor (SBTI) instead of complete medium to inactivate trypsin and prevent cell clumping. We use trypsin-EDTA solution without phenol red to avoid background fluorescence.
• We pass suspension cells and trypsinized adherent cells through a 40-μm cell strainer before sorting, to ensure that cells are mostly single. This prevents clogging of the cell sorter nozzle, which is important when doing prolonged cell sorts.
• When performing multi-color FACS, fluorescence compensation is critical because of the overlap of fluorochrome emission spectra. For this reason, our pHR-CMV-TetO 2 suite contains plasmids for the expression of free cytosolic EmGFP, mVenus, mRuby2 and mTurquoise2. Cells expressing these fluorochromes can be used as bright positive-control samples. Non-transduced cells serve as negative-control samples. Combined, these control samples serve to properly set photomultiplier tube (PMT) detector voltages and to calculate the fluorescence compensation matrix.
• Fluorescence-minus-one (FMO) control samples are cells expressing all but one of the fluorochromes. They ensure that spread of fluorochromes into the channel of interest is properly identified and are ideal for determining accurate gating boundaries.
• Viability dyes such as propidium iodide (PI), DRAQ7, 7-AAD or TO-PRO-3 that penetrate dead and dying cells and bind their DNA can be used to design a gating strategy to remove these cells from the transduced cell population or to monitor cell viability to decide on the appropriate time for harvesting of expression cells or conditioned medium.
• When using inducible cells, FACS can be performed using either uninduced 65 or Dox-induced fluorescence. Importantly, the 405 nm laser readily excites Dox, introducing potential bias into fluorescence measurements. Therefore, we induce protein expression 24-48 h before sorting, using only 0.1 μg/mL Dox, and spin down the cells (500g for 5 min at room temperature (22-24 ºC)) and resuspend them in Dox-free medium (without phenol red) or carrier buffer just before cell sorting. FACS compensation and FMO control samples are treated identically. Finally, we return the sorted cells to Dox-free growth medium after sorting. Representative −Dox and +Dox fluorescence of HEK293S GnTI − TetR cells expressing the membrane proteins SMO XTAL and GABA A R-β3 FL is shown in Fig. 4c and Fig. 5c Fig. 3 ).
Co-transduction of different transgenes
Co-infection of cells using separate viruses encoding different transgenes (using FP fusions or using the IRES-FP variants) is useful for the expression of heteromeric receptors or protein complexes. Co-infected cells expressing all subunits can be enriched using multi-color FACS (Box 3).
In vivo biotinylation
In vivo biotinylation is a convenient way of introducing a biotin label into a specific 15-residue acceptor sequence ('Avi-tag'; GLNDIFEAQKIEWHE in single-letter amino acid code). We have constructed the pHR-CMV-TetO 2 _HA-BirA (5.0-kb proviral DNA size) and pHR-CMV-TetO 2 _HA- (Table 1) . Co-transduction of target cells with lentiviruses encoding HA-BirA or HA-BirA-ER, and lentiviruses encoding the transgene of interest carrying an Avi-tag, leads to site-specific biotinylation of the transgene in the presence of D-biotin. The choice for BirA or BirA-ER is determined by the subcellular location of the Avi-tag during protein trafficking; BirA-ER is used when the Avi-tag is located in the ER lumen, and BirA is used when the Avi-tag is located in cytoplasm. We routinely use in vivo biotinylation to produce biotinylated protein ligands for biophysical analysis (e.g., surface plasmon resonance (SPR), bio-layer interferometry (BLI)) or for immunohistochemistry. Finally, we constructed the 3C-Avi-His6_IRES-HA-BirA-ER plasmid variant to allow bicistronic expression of Avi-His6-tagged transgene and HA-BirA-ER (Table 1 and Supplementary Fig. 3) .
PROTOCOL NATURE PROTOCOLS
BirA-ER (5.2-kb proviral DNA size) transfer plasmids that direct the expression of intracellular or endoplasmic reticulum (ER
Generation of inducible cell lines
We constructed the pHR-CMV_TetR-HA-NLS-P2A-BSD-Myc transfer plasmid that leads to constitutive expression of HA-tagged TetR and c-Myc-tagged blasticidin deaminase (BSD) from a single transcript (Table 1 ). The plasmid can be used to make the expression cell line of choice inducible and allows blasticidin selection of the transduced cell pool. It is an alternative to the pcDNA6/TR vector (Thermo Fisher Scientific) with which the HEK293S GnTI − TetR cell line was originally constructed 34 . The 2A peptide from porcine teschovirus-1 (P2A) directs ribosomal skipping during translation and ensures that TetR and BSD occur as two separate proteins 39 . In addition, we added the SV40 nuclear localization signal (NLS) to TetR to increase its nuclear localization.
Comparison with other methods
The main advantages of our method over transient transfection 3 are that (i) no large-scale DNA preps (e.g., Mega-or Gigapreps) are necessary because a single miniprep is sufficient; (ii) no tedious largescale transfection procedures are necessary; (iii) established cell lines can be stored in liquid nitrogen (LN 2 ) and re-grown when required; (iv) efficient transduction optionally preceded by lentivirus concentration and/or followed by FACS-based enrichment yields close to 100% protein-expressing cells; (v) inducible large-scale expression is greatly facilitated and (vi) protein production yields are larger.
The main advantages of our method over the establishment of a monoclonal stable cell line are simplicity and time efficiency; a polyclonal stable cell line is generated in~7 d using our procedure, whereas establishment and selection of stably transfected monoclonal cell lines is laborious and typically takes up to 8-10 weeks 4 . Rigorous selection of monoclonal cell lines can lead to isolation of only the most potently expressing cell clones; it is of note that the use of the IRES-FP plasmid variants allows the isolation of single cells or the enrichment of subsets of cells from the total transduced cell pool using FACS (Box 3). If the user should wish so, the IRES-FP elements can readily be replaced with IRES followed by an antibiotic selection marker gene of choice, such as ble (zeocin resistance), neor (geneticin/G418 resistance), pac (puromycin resistance) or bsd (blasticidin resistance).
piggyBac (PB), a DNA transposon from the cabbage looper moth Trichoplusia ni, is emerging as an effective tool for the generation of inducible, stably transfected mammalian cell lines for large-scale protein production 40, 41 . Like lentivirus, the piggyBac-based system achieves high and uniform expression levels. Stably transfected cells must be selected with antibiotic for~2-3 weeks before scale up to bulk cell culture.
BacMam 42, 43 is the use of baculovirus to transiently deliver genes to mammalian cells. It has been widely used for both screening and large-scale expression of membrane protein constructs 44, 45 . A key advantage of our method is that lentiviral transduction leads to stable transgene expression, and that successful cell lines can be stored. In addition, no dedicated infrastructure, media, cell lines or consumables to sustain working with insect cells are necessary. Moreover, the generation of lentivirus is substantially easier and faster than the production of the large quantities of P1 and P2 BacMam virus that are needed to infect large volumes of expression cells 44 . Lentivirus therefore has a much smaller laboratory footprint than BacMam. Comparative advantages of BacMam are that baculovirus requires only biosafety level 1 (BSL1) practices and that it is able to carry very large (>15 kb) 42 or multiple inserts. The latter issue can, however, be circumvented by co-infecting expression cells with multiple lentiviruses and enriching them using multi-color FACS (using the IRES-FP plasmid variants; see Box 3). 
Biological safety considerations
The lentiviral expression system requires biosafety level 2 (BSL2) or 2+ (BSL2+) practices, depending on the relevant institutional and governmental biosafety guidelines. The two main safety concerns surrounding the use of lentivirus are (i) the potential for generation of replication-competent lentivirus (RCL) and (ii) the potential for oncogenesis.
The potential for generation of RCL is determined by the specific design of the plasmids. The second-generation lentiviral system described here separates transfer, envelope and packaging components of the lentivirus among three separate plasmids. Although third-generation lentiviral vectors further improve on the safety of the second generation by splitting the packaging system into two separate plasmids 46 , they are more cumbersome to use and result in lower viral titers due to the requirement of one additional plasmid.
The transfer plasmid contains the sequences that will incorporate into the host cell genome, but functional viral particles cannot be produced from it without the genes encoded in the envelope and packaging plasmids. Simultaneous recombination events among the packaging, envelope and transfer plasmids that produce RCLs are very unlikely. Replication-competent retroviruses (RCRs) have, however, been reported 47 . The pHR-CMV-TetO 2 plasmids are all self-inactivating (SIN 48, 49 ); they have a deletion in the 3ʹ LTR (ΔU3) of the viral genome that is transferred into the 5ʹ LTR after one round of reverse transcription. This deletion abolishes transcription of the full-length proviral DNA. SIN vectors also reduce the possibility of recombination to generate RCLs.
The potential for oncogenesis is largely based on the specific insert contained within the lentiviral transfer plasmid and should be considered on a case-by-case basis.
To mitigate risks even further, we do not routinely concentrate the viral supernatant to make lentiviral stock solutions. We directly transfer the lentivirus-containing supernatant to the expression cells (Steps 11-17 in the Procedure) and use FACS to enrich transduced cell populations. This limits the time that researchers are working with viral particles that are outside of a sealed container and also prevents the viral supernatant from exiting the laminar flow cabinet.
Below is a list of risk reduction measures routinely undertaken within our laboratory: • Only specially trained and signed-off laboratory staff are authorized to carry out Class II viral work.
• Appropriate personal protective equipment (PPE) is worn at all times: laboratory coat, safety eyewear and disposable long-cuff gloves.
• Proper decontamination of the working area is performed with 1% (wt/vol) Virkon when working with lentiviral particles, both before the work begins and after the work is completed.
• All manipulations with respect to lentiviral particle generation, packaging, harvesting and infection are carried out in a Class II microbiological safety cabinet (MSC).
• A dedicated CO 2 cell culture incubator, with affixed warning sign, is used for all lentiviral work.
• Care is taken to prevent production of aerosols that may contain viral particles during all liquidhandling steps.
• In the case of accidental spillage, surfaces and items are carefully decontaminated using 1% (wt/vol) Virkon.
• All materials exposed to viral supernatant are rinsed with 1% (wt/vol) Virkon before being disposed of into an autoclave bag. These bags are then placed in the biological waste containers for autoclaving as soon as the work is complete.
Materials Biological materials
! CAUTION The cell lines used in your research should be regularly checked to ensure they are authentic and are not infected with mycoplasma.
• HEK293T Lenti-X cells (Takara/Clontech, cat. no. 
Reagent setup
DMEM/F-12/10% FBS Add 50 mL of (10% (vol/vol)) FBS and 5 mL of (1% (vol/vol)) NEAA to 445 mL of DMEM/F-12. The medium can be stored at 4°C as long as there are no visual signs of infection or contamination.
DMEM/F-12/2% FBS Add 10 mL of (2% (vol/vol)) FBS and 5 mL of (1% (vol/vol)) NEAA to 485 mL of DMEM/F-12. The medium can be stored at 4°C as long as there are no visual signs of infection or contamination.
DMEM/F-12/SFM (serum-free medium) Add 5 mL of (1% (vol/vol)) NEAA to 495 mL of DMEM/F-12. The medium can be stored at 4°C as long as there are no visual signs of infection or contamination.
FreeStyle 293/1% FBS Add 5 mL of (1% (vol/vol)) FBS and 5 mL of (1% (vol/vol)) NEAA to 490 mL of FreeStyle 293. The medium can be stored at 4°C as long as there are no visual signs of infection or contamination.
PEI (1 mg/mL stock)
The PEI stock solution is highly viscous and cannot be pipetted. First, pour and weigh 1-5 mL straight from the bottle into a 50-mL tube. PEI has a density of 1.030 g/mL at 25°C. Add ultrapure water to prepare a 100-mg/mL stock solution. Rotate the tube overnight to mix. Once the solution is PROTOCOL NATURE PROTOCOLS homogeneous, dilute it to 1 mg/mL in ultrapure water and adjust the pH to 7.0 with hydrochloric acid (HCl). Filter-sterilize, using a 0.2-μm syringe filter unit inside a biological safety cabinet. Make aliquots and store at −20°C for up to 1 year. Dox (10 mg/mL stock) Dissolve 50 mg in 100% (vol/vol) ethanol to a final volume of 5 mL and filter-sterilize, using a 0.2-μm syringe filter unit inside a biological safety cabinet. Make aliquots and store at −20°C for up to 8 weeks.
c CRITICAL Do not expose Dox to direct sunlight.
Blasticidin (2 mg/mL stock) Dissolve 20 mg in ultrapure water to a final volume of 10 mL and filter-sterilize, using a 0.2-μm syringe filter unit. Make aliquots and store at −20°C for up to 8 weeks. ! CAUTION Blasticidin is toxic. Always wear PPE: laboratory coat, safety eyewear and disposable long-cuff gloves. Weigh the powder in a chemical safety cabinet and prepare the solution inside a biological safety cabinet.
Sodium butyrate (500 mM stock) Dissolve 1.1 g of sodium butyrate in ultrapure water to a final volume of 20 mL and filter-sterilize, using a 0.2-μm syringe filter unit inside a biological safety cabinet. Make aliquots and store at −20°C for up to 8 weeks.
VPA (500 mM stock) Dissolve 1.66 g of VPA in ultrapure water to a final volume of 20 mL and filter-sterilize, using a 0.2-μm syringe filter unit inside a biological safety cabinet. Make aliquots and store at −20°C for up to 8 weeks.
Kifunensine (500 μM stock) Dissolve 11.6 mg of kifunensine in ultrapure water to a final volume of 100 mL and filter-sterilize, using a 0.2-μm syringe filter unit inside a biological safety cabinet. Make aliquots and store at −20°C for up to 1 year.
D-biotin (2 mM stock)
Dissolve 97.7 mg of D-biotin in 1× PBS to a final volume of 200 mL and filter-sterilize, using a 0.2-μm syringe filter unit inside a biological safety cabinet. Make aliquots and store at −20°C for up to 1 year.
5-aza-dC (10 mM stock)
Dissolve 10 mg of 5-aza-dC in 438 μL of DMSO to obtain a 100 mM stock. Dilute 1:10 (vol/vol) in 1× PBS to obtain the final 10 mM stock. Make aliquots and store at −20°C for up to 1 year 50 . ! CAUTION 5-aza-dC is toxic. Always wear PPE: laboratory coat, safety eyewear and disposable long-cuff gloves. Prepare the solution inside a biological safety cabinet. 5-aza-dC is supplied in a glass bottle or insert, ready for dissolution.
SBTI (1 mg/mL stock)
Dissolve 10 mg of SBTI in PBS to a final volume of 10 mL and filter-sterilize, using a 0.2-μm syringe filter unit inside a biological safety cabinet. 0.5 mg (= 0.5 mL) of SBTI stock solution will inhibit 0.5 mg of trypsin (or 1 mL of a 0.05% (wt/vol) trypsin solution), assuming a specific activity of 10,000 N α -benzoyl-L-arginine ethyl ester (BAEE) units/mg SBTI protein. We use 1 mL of SBTI per milliliter of a 0.05% (wt/vol) trypsin solution, yielding a 2:1 (wt/wt) SBTI/trypsin ratio. Make aliquots and store at −20°C for up to 1 year. 
Purification of plasmid DNA

Equipment setup
Shimadzu Prominence high-performance liquid chromatography (HPLC) system. We essentially perform established procedures for fluorescence-detection size-exclusion chromatography-based thermostability screening (FSEC-TS) 51, 52 .
Erlenmeyer flasks
The polycarbonate Erlenmeyer flasks for suspension cell culture can be washed, autoclaved and reused. When the vented caps deteriorate after rounds of autoclaving, the caps can be separately purchased and replaced.
Procedure
HEK293T Lenti-X cell seeding (Day 1) • Timing~1 d
1 Add~9 × 10 6 HEK293T Lenti-X cells in 12 mL of DMEM/F-12/10% FBS medium to a fresh T75 flask, bringing them to~50% confluency. Cell culture is described in detail in Box 1. ! CAUTION Cell cultures are a potential biological hazard. Working with HEK293 cells requires BSL2 practices. Perform the work in an approved laminar flow cabinet, using sterile techniques, and comply with the appropriate institutional biosafety guidelines. This includes wearing protective clothing and eyewear, cleaning of working surfaces, and proper disposal of waste before and after performing experiments. c CRITICAL STEP Lentivirus can be produced from regular HEK293T cells, but the HEK293 Lenti-X cell line used here has been clonally selected to yield viral titers~30× higher than those of HEK293T cells and~6× higher than those of HEK293FT cells, according to the manufacturer (Takara/Clontech). c CRITICAL STEP The health of the HEK293T Lenti-X producer cell line is critical to obtaining maximal lentiviral titer for downstream transduction. Maintain it diligently and split the cells 1/6 twice a week at fixed times; we suggest Monday morning and Thursday afternoon. We do not use the cells beyond passage 20 (P20;~10 weeks of culture) to ensure maximum viability and viral yield. ? TROUBLESHOOTING
HEK293T Lenti-X cell transfection (Day 2) • Timing~3 d
2 The next day, prepare the following plasmid DNA transfection mix (30 μg of total DNA; 1:1:1 (wt/wt/wt) transfer/packaging/envelope plasmid ratio) in a sterile 1.5-mL tube: 10 μg pHR-CMV-TetO 2 transfer plasmid variant containing the gene of interest 10 μg psPAX2 packaging plasmid 10 μg pMD2.G envelope plasmid Top up the transfection mix with DMEM/F-12/SFM medium to a total volume of 0.25 mL and gently mix the suspension. ? TROUBLESHOOTING 3 Prepare 75 μL of PEI (1:2.5 (wt/wt) DNA:PEI ratio) in a sterile 1.5-mL tube. Top up with DMEM/F-12/SFM medium to a total volume of 0.25 mL and gently mix the suspension. 4 When both solutions are ready, add the 0.25 mL of PEI mix to the 0.25 mL of plasmid DNA transfection mix for a total of 0.5 mL in a 1.5-mL tube. c CRITICAL STEP In our experience, both the volume in which the DNA/PEI transfection mix is prepared, and the DNA/PEI ratio, have a great effect on the transfection efficiency. We recommend adhering to the values stated in Steps 2-4. 5 Vortex the 1.5-mL tube gently for 10 s, then centrifuge it briefly at low speed (100g, 22-24°C, 30 s) to collect the liquid at the bottom of the tube, and then leave it for incubation in the flow cabinet for 15-20 min. 6 The T75 flask with HEK293T Lenti-X cells is now >90% confluent (continued from Step 1); remove and discard the DMEM/F-12/10% FBS medium; wash with 10 mL of PBS and replace the medium with 11.5 mL of DMEM/F-12/2% FBS medium. 7 Add the 0.5 mL of DNA/PEI mix to the 11.5 mL of DMEM/F-12/2% FBS medium for a total of 12 mL, and gently tilt flask to cover all cells. ? TROUBLESHOOTING 8 Place the T75 flask back at 37°C in a humidified incubator operated at 5% CO 2 .
! CAUTION Lentiviral particles are a potential biological hazard and require BSL2 or BSL2+ practices, depending on the relevant institutional and governmental biosafety guidelines. Perform the work in an approved laminar flow cabinet, using sterile technique, and comply with the relevant PROTOCOL NATURE PROTOCOLS 3006 institutional biosafety guidelines. A list of risk reduction measures can be found in the 'Biological safety considerations' section of the main text. c CRITICAL STEP The transfection can also be performed in small-scale T25 format or in a T175 flask. The required amounts of plasmid DNA and PEI must be scaled with flask surface area. The T25 format allows the simultaneous screening of multiple constructs and expression conditions before scale-up, whereas using T175 flasks has the advantage that downstream scale-up is quicker. When performing transfections in T25 format, we use 10 μg of total DNA (1:1:1 (wt/wt/wt) ratio) and a total transfection mix volume of 200 μL (100 + 100 μL) is added to 4 mL of DMEM/F-12/2% FBS medium. When performing transfections in T175 format, we use 70 μg of total DNA (1:1:1 (wt/wt/wt) ratio) and a total transfection mix volume of 1.0 mL (0.5 + 0.5 mL) is added to 30 mL of DMEM/F-12/2% FBS medium. For co-transfection of different transfer plasmids, we usually divide the total amount of transfer plasmid DNA in equal parts (e.g., for a three-plasmid co-transfection in a T75 flask, we use 3.3 μg of each transfer plasmid). Transfer plasmid ratios should, however, be optimized in situations in which there is a large difference in proviral DNA size between the transfer plasmids, to ensure approximately equal viral titers for the most efficient co-transduction.
HEK293T, HEK293S GnTI
− or HEK293S GnTI flask into a sterile 50-mL tube. This contains the lentiviral particles. 12 Add 6 mL of fresh DMEM/F-12/10% FBS medium to the 50-mL tube, yielding a total of 18 mL. 13 Filter the conditioned medium through a 0.45-μm filter unit attached to a Luer-lock syringe and into a new sterile 50-mL tube. c CRITICAL STEP Do not use a 0.22-μm filter unit, because this may shear the viral particles. Use only cellulose acetate or polyethersulfone (PES) (low-protein-binding) filters. Avoid the use of nitrocellulose filters; these bind lentiviral envelope proteins and destroy the virus. 14 Add 18 μL (from a 10-mg/mL 1,000× stock solution) of polybrene to the 18 mL of lentiviruscontaining medium and mix gently. Polybrene (hexadimethrine bromide) is a cationic polymer that reduces charge repulsion between viral particles and the cell membrane 53 . It will promote virus-host cell fusion, leading to higher transduction efficiencies. Optional determination of lentiviral titer is described in Box 2. It is a good idea to cryopreserve the polyclonal stable HEK293 cell line, in LN 2 and in the presence of a cryoprotective agent such as DMSO directly after establishment or enrichment. Procedure 1 Gently dislodge and resuspend the adherent cells from the T75 flask in DMEM/F-12/10% FBS medium, using a sterile serological 10-mL pipette; pipette up and down a few times to break up cell clumps. Alternatively, cells can be trypsinized. 2 Centrifuge the cells at 500g for 5 min at room temperature (22-24°C) , and discard the supernatant without disturbing the cell pellet. 3 Resuspend the cells in 9 mL of DMEM/F-12/10% FBS medium containing 10% (vol/vol) DMSO; this leads to a minimally recommended cell density of~2.0 × 10 6 cells/mL. 4 Dispense aliquots of the cell suspension into cryogenic storage vials. Mix the cells frequently and gently during this process to maintain a homogeneous cell suspension. 5 Place the cryovials in an isopropanol cooling chamber and store the chamber at -80°C overnight for controlled cooling. 6 Finally, transfer and store the cryovials in the gas phase above the LN 2 . 7 To restart the cell culture, place a cryovial containing frozen cells in a 37°C water bath for a maximum of 1 min to rapidly thaw them. 8 Slowly dilute the thawed cells using pre-warmed DMEM/F-12/10% FBS medium. 9 Plate the thawed cells at high density to optimize their recovery (e.g., use the contents of one cryovial per T75 flask). c CRITICAL STEP The thawing procedure is stressful to cryopreserved cells; use good technique and work quickly to ensure that most of the cells survive the procedure.
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Troubleshooting
Troubleshooting advice can be found in Table 2 .
Timing
The entire protocol, starting from the transfection of Lenti-X cells to the liter-scale collection of conditioned medium containing secreted protein, or suspension cells containing membrane or intracellular proteins, takes~3-4 weeks. The timing for each stage of the Procedure is summarized below.
Step 1, HEK293T Lenti-X cell seeding:~1 d Step 22A(i-v), expansion of the adherent polyclonal cell line:~8 d
Step 22A(vi-xi), protein expression:~5-10 d
Step 22A(xii and xiii), collection of expressed protein:~1 h
Step 22B(i-xviii), expansion of the polyclonal HEK293S GnTI − TetR cell line for suspension growth:
d
Step 22B(xix-xxi), induction of the polyclonal HEK293S GnTI − TetR cell line and protein expression:
1-3 d
Step 22B(xxii), collection of cell pellets:~1 h Box 2, endpoint dilution assay to determine functional lentiviral titer:~4 d Box 4, long-term storage of cell lines in LN 2 :~1 h
Anticipated results
The described protocols are used within our laboratories at STRUBI and the MRC-LMB to express a large number of soluble and membrane proteins varying in size, topology and oligomeric state, as well as protein complexes. The time required to identify promising constructs varies considerably on a case-by-case basis. For soluble proteins, we identify constructs suitable for scale-up by evaluating their transient or stable expression and secretion in small-scale format using western blotting. For membrane proteins, we follow established procedures for FSEC-TS 51, 52 . We emphasize the importance of exploring expression time, expression temperature and Dox concentration as variables 44 . Given the scalability of the method, polyclonal cell lines can be readily established and expanded in small-scale adherent cultures or low-volume suspension cultures, allowing the simultaneous screening of these variables before scale-up.
Examples illustrating the protocol
To illustrate the broad applicability of the method, we cloned a set of cDNA inserts into the various pHR-CMV-TetO 2 plasmids. These inserts code for neuronal proteins of varying sizes, folds and expression levels and have been previously successfully transiently expressed in HEK293 cells using the pHLsec plasmid. We compared secreted and whole-cell protein levels from HEK293T cells transduced with nonconcentrated lentiviral particles (pHR-CMV-TetO 2 _3C-Avi-His6 plasmid) in T25-flask format, with levels from HEK293T cells transiently transfected with equimolar amounts of either the pHLsec or the pHR-CMV-TetO 2 _3C-Avi-His6 plasmid, using anti-His6 western blotting. For all targets, we noted markedly increased levels of protein production and secretion from the lentivirus-transduced cells, regardless of proviral DNA size and absolute expression levels. Interestingly, we also observed higher transient expression levels using pHR-CMV-TetO 2 as compared with pHLsec, indicating that pHR-CMV-TetO 2 is very well suited to initial transient small-scale screening of expression constructs and that subcloning in pHLsec is unnecessary for this purpose (Fig. 2c) . For the large-scale (12 roller bottles) production of axon guidance molecules Netrin-1 (NET1 ΔNTR ) and Neogenin-1 (NEO1 FN456 ) 55,56 , we achieved a threefold and fourfold improvement in secreted protein yield after purification, respectively, when using stable lentiviral expression as compared to transient expression using pHLsec (Fig. 2d) .
We compared secreted and whole-cell protein levels from HEK293T cells transduced with nonconcentrated lentiviral particles produced using the pHR-CMV-TetO 2 _3C-Avi-His6 or pHR-CMVTetO 2 _3C-Avi-His6_IRES-EmGFP plasmid variant, using anti-His6 western blotting (Fig. 3e) . Interestingly, although markedly lower signal was observed from the cell pellets of the IRES-EmGFP samples, the levels of secreted protein were not adversely affected. For the α-NRX1 ECTO-FL construct, a marked increase in secreted protein levels was even observed. In summary, we prefer to use the IRES-FP plasmid variants over the non-IRES-FP plasmid variants because they lead to at least as much secreted protein while also enabling routine verification of transfection and transduction efficiency, using fluorescence microscopy or flow cytometry, as well as enrichment of the cell line using FACS. As an example, we established a polyclonal stable cell line for 3C-Avi-His6-tagged MDGA1 ECTO-FL 33 (8.2-kb proviral DNA). Using flow cytometry, we measured a transduction efficiency of~94% (Fig. 3f) . We applied this sort gate and expanded the sorted cells into four roller bottles (1 L of DMEM/F-12/2% FBS medium). From this volume, we obtained~47 mg of purified secreted MDGA1 ECTO-FL , as compared with~7 mg from large-scale transient transfection using pHLsec (Fig. 3g) .
We further illustrate the usefulness of the method for membrane proteins using the GPCR SMO 57 and the GABA A R β3 homopentamer 58 . We established polyclonal stable HEK293S GnTI − TetR cell lines for mVenus-fused SMO XTAL (6.8-kb proviral DNA; Fig. 4 (top and center panels) ) and mVenusfused full-length GABA A R-β3 (GABA A R-β3 FL ; 5.7-kb proviral DNA; Fig. 5 (top and center panels) ), using non-concentrated lentiviral particles. 72 h post transduction, we initiated suspension culture. After 48 h, we induced gene expression for 24 h, using Dox. For both SMO XTAL (Fig. 4c,d ) and GABA A R-β3 FL (Fig. 5c,d ), we determined, using flow cytometry, that~90% of gated suspension HEK293S GnTI − TetR cells robustly expressed protein. Interestingly, the analysis also revealed that repression of GABA A R-β3 FL expression was more efficient (less 'leaky') than that of SMO XTAL , leading to a larger fold change in median fluorescence intensity (MFI) upon Dox application (Figs. 4c  and 5c ).
To determine the optimal expression parameters for SMO XTAL , we expanded the polyclonal stable HEK293S GnTI − TetR cell line into 6-well format and performed an FSEC screen, varying Dox concentration (0.0, 0.1, 1.0 and 10 μg/mL), expression temperature (30 and 37°C 44 ) and collection PROTOCOL NATURE PROTOCOLS time (24, 48 and 72 h) . From the analysis, we determined that SMO XTAL expression is best when induced using 0.1 or 1.0 μg/mL Dox and collected after 72 h at 37°C (Fig. 4e) . We routinely perform this FSEC analysis for our membrane protein samples; it takes <24 h to screen a total of 24 conditions using an automated HPLC system. The 0.0 μg/mL Dox samples serve as negative controls. We compared the BacMam procedure 44, 45 with our lentiviral procedure for the expression of GABA A R-β3 FL , using FSEC. Common screening parameters were expression temperature (30 and 37°C), collection time (24, 48 and 72 h), and additives (5 mM VPA or sodium butyrate). For BacMam and lentiviral transduction, we additionally screened MOI ratios (0, 1, 4 and 10) or Dox concentration (0, 5 and 10 μg/mL), respectively ( Supplementary Fig. 7a,b) . From this matrix of conditions, we determined that in the case of lentiviral transduction, inducible expression at 37°C for 24 h without additives or at 30°C for 72 h with 5 mM sodium butyrate is optimal, whereas in the case . b, Non-concentrated lentiviral particles encoding mVenus-GABA A R-β3 FL -1D4 were used to infect adherent HEK293S GnTI − TetR cells. c, Flow cytometry analysis of non-transduced (negative control) and transduced (−Dox and +Dox, respectively) cells after trypsinization and suspension growth. Dox (5 μg/mL Dox for 24 h) was added when the suspension cell density reached~1.0 × 10 6 cells/mL. d, Fluorescence microscopy imaging of transduced (+Dox and −Dox) adherent cells. Images were taken on a Leica SP8 SMD X confocal microscope. Fluorescence emission was detected using hybrid detectors operated in photon-counting mode, meaning that each incident photon gave rise to one gray value. Scale bar, 100 μm. e, Comparative lentivirus vs. BacMam FSEC screening. mVenus-GABA A R-β3 FL -1D4 yield using lentiviral transduction is approximately fivefold greater than using BacMam when comparing the best respective conditions ( Supplementary Fig. 7a,b) . 1D4, 1D4 tag; 3C, 3C protease cleavage site; DIC, differential interference contrast; ECD, extracellular domain; ICD, intracellular domain; MFI, median fluorescence intensity; MOI, multiplicity of infection; SS, signal sequence; TMD, transmembrane domain. of BacMam, expression at 30°C for 72 h using an MOI ratio of 10 as well as 5 mM sodium butyrate is optimal. However, protein yield using lentiviral transduction was at least fivefold greater than using BacMam when comparing the best respective conditions (Fig. 5e and Supplementary Fig. 7a,b) .
For co-infection of cells using lentiviruses encoding distinct transgenes, two strategies can be followed: (i) separately produced lentiviruses can be mixed in the desired stoichiometric ratio after titer determination or (ii) multiple pHR-CMV-TetO 2 plasmids can be co-transfected into the HEK293T Lenti-X producer cell line. In both cases, co-transduced cells can then be enriched using multi-color FACS. We applied the second strategy to the secreted Cbln1 FL -β-NRX1 LNS6 complex 32 (Fig. 6a) ; from the total transduced cells pool (Fig. 6b) , the subset of cells expressing both transgenes was isolated using FACS and using IRES-EmGFP and IRES-mRuby2 fluorescence (Fig. 6c,d) . The approach can be extended to multi-subunit complexes using more fluorochromes; our plasmid suite currently supports up to three colors (IRES-EmGFP, IRES-mRuby2 and IRES-mTurquoise2; Supplementary Fig. 8a,b) , but this can be readily modified or extended because the IRES-FP elements can be excised and replaced using the unique XhoI-BsiWI restriction sites (Supplementary Fig. 3 ). 
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To illustrate in vivo biotinylation, we either (i) co-infected HEK293T cells with non-concentrated lentiviral particles encoding HA-tagged ER-resident BirA (HA-BirA-ER) and lentiviral particles encoding 3C-Avi-His6-tagged NL1 ECTO (Fig. 6e) or (ii) performed bicistronic expression of NL1 ECTO and HA-BirA-ER using the 3C-Avi-His6_IRES-HA-BirA-ER plasmid (Fig. 6f) . D-biotin was maintained in the DMEM/F-12/2% FBS medium at 100 μM. Using western blotting, we confirmed successful biotinylation of secreted NL1 ECTO (Fig. 6e,f) .
Finally, we generated inducible HEK293T and HEK293S GnTI − cells by infecting them with nonconcentrated lentiviral particles encoding TetR-HA-NLS-P2A-BSD-Myc. After two passages that included selection with 10 μg/mL blasticidin to kill non-transduced cells, we infected the resulting HEK293T lenti-TetR and HEK293S GnTI − lenti-TetR cell lines with non-concentrated lentiviral particles encoding cytosolic mVenus (Fig. 6g) . Using flow cytometry, we confirmed inducible mVenus expression in both polyclonal cell lines (Fig. 6h) . Interestingly, HEK293S GnTI − lenti-TetR cells showed less uninduced ('leaky') mVenus expression than HEK293S GnTI − TetR cells, leading to a larger fold change in MFI upon Dox application (Fig. 6h) .
Reporting Summary
Further information on research design is available in the Nature Research Reporting Summary.
